John T. Curnutte
2017
In 2017, John T. Curnutte earned a total compensation of $2.1M as Executive Vice President, Research and Development at Portola Pharmaceuticals, a 9% decrease compared to previous year.
Compensation breakdown
| Bonus | $30,000 |
|---|---|
| Non-Equity Incentive Plan | $240,608 |
| Option Awards | $767,210 |
| Salary | $417,723 |
| Stock Awards | $638,500 |
| Other | $39,013 |
| Total | $2,133,054 |
Curnutte received $767.2K in option awards, accounting for 36% of the total pay in 2017.
Curnutte also received $30K in bonus, $240.6K in non-equity incentive plan, $417.7K in salary, $638.5K in stock awards and $39K in other compensation.
Rankings
In 2017, John T. Curnutte's compensation ranked 5,203rd out of 14,666 executives tracked by ExecPay. In other words, Curnutte earned more than 64.5% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 5,203 out of 14,666 | 65th |
Division Manufacturing | 1,855 out of 5,768 | 68th |
Major group Chemicals And Allied Products | 551 out of 2,074 | 73rd |
Industry group Drugs | 425 out of 1,730 | 75th |
Industry Pharmaceutical Preparations | 334 out of 1,329 | 75th |
Source: SEC filing on April 24, 2018.
Curnutte's colleagues
We found four more compensation records of executives who worked with John T. Curnutte at Portola Pharmaceuticals in 2017.